The Company’s History: From Neurology to Immunology
Climb Bio, Inc. (formerly known as Eliem Therapeutics, Inc.) has undergone a transformative shift, shedding its previous focus on neurological disorders to concentrate solely on the development of treatments for immune-mediated diseases. This strategic pivot, marked by the acquisition of Tenet Medicines in June 2024, has positioned the company as a rising force in the burgeoning field of autoimmune therapies.
Climb Bio, Inc. was incorporated in Delaware in October 2018 under the name Eliem Therapeutics, Inc. The company’s initial focus was on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. Their lead program was ETX-123, a Kv7.2/3 potassium channel opener designed to improve the safety and tolerability relative to earlier molecules.
In July 2023, the company made a strategic decision to pause further development of its Kv7 program and comprehensively explore strategic alternatives. This decision came after a thorough review of the company’s business, including the status of their programs, resources, and capabilities. Concurrent with this strategic shift, Eliem entered into a securities purchase agreement for a $120 million private placement.
The pivotal moment for Eliem came on June 27, 2024, with the completion of its acquisition of Tenet Medicines, Inc., a private, development-stage biotechnology company. Tenet was majority-owned by funds affiliated with RA Capital Management prior to the acquisition. In connection with the closing of the acquisition, Eliem issued and sold 31.24 million shares of its common stock at $3.84 per share in the $120 million private placement.
This strategic move not only added a clinical-stage program to Eliem’s pipeline but also realigned the company’s core focus towards addressing unmet needs in autoantibody-mediated diseases. Following the acquisition, Eliem shifted its focus entirely from developing therapeutics for neuronal excitability disorders to immune-mediated diseases.
As part of this transformation, the company’s lead program became budoprutug (previously referred to as TNT119), an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. In the third quarter of 2024, Eliem ceased its operations in the United Kingdom and separated from seven U.K. employees as part of this shift in focus, further streamlining its operations to align with its new strategic direction.
Budoprutug’s Promising Clinical Data
The Phase 1b clinical trial of budoprutug in pMN has yielded encouraging results, with 3 out of 5 (or 60%) of patients who received all four doses of the study drug achieving complete remission of proteinuria, a key symptom of pMN, at week 48. Additionally, a complete and sustained B-cell depletion was observed in all patients, with undetectable levels of B-cells occurring after just two doses of the study drug.
These findings, along with the favorable safety profile observed in the trial, have further bolstered the company’s confidence in budoprutug’s potential as a disease-modifying treatment for autoantibody-driven diseases. Climb Bio plans to advance budoprutug into late-phase clinical development for pMN in 2025, while also initiating Phase 1b and Phase 2 trials for SLE and ITP, respectively, in the first half of 2025.
Strengthening the Leadership Team
In tandem with the strategic shift, Climb Bio has strengthened its leadership team with the appointments of key executives. In August 2024, the company welcomed Brett Kaplan, M.D., as Chief Operating Officer, and Nishi Rampal, M.D., as Senior Vice President of Clinical Development, further bolstering its capabilities in advancing its pipeline of immune-mediated disease treatments.
Financials and Liquidity
Climb Bio’s financial position has been significantly bolstered by the Tenet Medicines acquisition and the concurrent $120 million private placement. As of September 30, 2024, the company reported cash, cash equivalents, and marketable securities of $217.9 million, which it estimates will be sufficient to fund operations through 2027. This strong cash runway is expected to enable the company to achieve key clinical and development milestones for budoprutug, as well as explore potential pipeline expansion opportunities.
For the most recent quarter (Q3 2024), Climb Bio reported no revenue and a net loss of $54,889,000. The operating cash flow (OCF) and free cash flow (FCF) for the quarter were both negative $667,000. The net loss increased significantly from $3,970,000 in Q3 2023 to $8,890,000 in Q3 2024, primarily due to increases in research and development expenses and general and administrative expenses related to the company’s transition to a focus on immune-mediated diseases.
The company’s liquidity position remains strong, with a debt-to-equity ratio of 0.0004 as of September 30, 2024. Cash and cash equivalents stood at $146.18 million, while both the current ratio and quick ratio were 60.41, indicating a robust ability to meet short-term obligations.
For the nine months ended September 30, 2024, Climb Bio reported a net loss of $65.48 million, compared to a net loss of $31.48 million in the same period of the prior year. The increase in net loss was primarily attributable to $51.66 million in acquired in-process research and development expenses related to the company’s acquisition of Tenet Medicines, Inc. in June 2024.
Navigating Regulatory Challenges and Industry Dynamics
As Climb Bio navigates the complex regulatory landscape and competitive dynamics of the pharmaceutical industry, the company faces several risks and challenges. The development and commercialization of new drug products is inherently uncertain, with the potential for delays, setbacks, and regulatory hurdles. Additionally, the company operates in a highly competitive environment, with larger pharmaceutical and biotechnology companies vying for market share.
Furthermore, Climb Bio’s financial performance and growth prospects are subject to macroeconomic conditions, including the potential impact of global events, supply chain disruptions, and inflationary pressures on salaries, wages, and costs of goods and transportation. The company’s ability to attract and retain key personnel, as well as its success in executing strategic partnerships and collaborations, will also be crucial in determining its long-term trajectory.
Conclusion
Climb Bio’s transition from a neurology-focused company to a leader in immune-mediated disease treatments represents a pivotal moment in the company’s history. The acquisition of Tenet Medicines and the advancement of budoprutug through late-stage clinical development have positioned the company to address significant unmet needs in the autoimmune disease landscape. With a strengthened leadership team, a robust financial position, and a promising pipeline, Climb Bio is poised to capitalize on the growing demand for innovative therapies that can effectively modulate the immune system and provide relief to patients suffering from a range of autoantibody-driven conditions.
The company’s focus on developing budoprutug for the treatment of immune-mediated diseases such as pMN, SLE, and ITP demonstrates its commitment to addressing unmet medical needs. The positive early clinical results for budoprutug in pMN and the planned advancement of the program through additional clinical trials underscore the potential of this lead product candidate. With a well-capitalized position following the recent private placement financing, Climb Bio is well-positioned to fund its operations and continue developing its pipeline for the next several years, potentially bringing innovative treatments to patients in need.
Disclaimer: This article is for informational purposes only. It does not constitute financial, legal, or other types of advice. While every effort has been made to ensure the accuracy of the information presented here, the author and the publisher do not make any guarantees about the completeness, reliability, and accuracy of this information.